CYPHERPUNK TECHNOLOGIES INC. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
CYPHERPUNK TECHNOLOGIES INC. (CYPH) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of $2.12 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-16
- CYPHERPUNK TECHNOLOGIES INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was $2.12M.
- CYPHERPUNK TECHNOLOGIES INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$14.06M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | $2.12M 10-K · filed 2026-03-16 |
| 2024-12-31 | -$14.06M 10-K · filed 2026-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |